Drug class
Once-weekly long-acting basal insulin analogue; insulin receptor agonist
Mechanism of action
Activates insulin receptors, promoting glucose uptake in skeletal muscle and adipose tissue and suppressing hepatic glucose production. The albumin-binding design extends systemic exposure and permits once-weekly administration.
General use cases
- Once-weekly basal insulin treatment to improve glycaemic control in adults with diabetes mellitus under the applicable Awiqli product authorisation; dose conversion and monitoring are product-specific
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
